Commercial aspects of pharmaceutical protein production in plants

Current Pharmaceutical Design

Volumn 19, Issue 31, 2013, Pages 5471-5477

  Fischer, Rainer ^a,b   Schillberg, Stefan ^a   Buyel, Johannes F ^a   Twyman, Richard M ^c  

^a FRAUNHOFER INSTITUTE FOR MOLECULAR BIOLOGY AND APPLIED ECOLOGY IME   (Germany)

^b RWTH AACHEN UNIVERSITY   (Germany)

^c TRM Ltd   (United Kingdom)

Author keywords

Biopharmaceutical; Disruptive technology; GMP; Innovation; Molecular farming; Platform technology

Indexed keywords

ANTIIDIOTYPIC ANTIBODY; INFLUENZA VACCINE; RECOMBINANT PROTEIN;

ARTICLE; CHROMATOGRAPHY; COMMERCIAL PHENOMENA; DOWNSTREAM PROCESSING; DRUG MANUFACTURE; ECONOMIC ASPECT; GLYCOSYLATION; GOOD MANUFACTURING PRACTICE; LARGE SCALE PRODUCTION; LAW; MOLECULAR FARMING; NONHUMAN; PLANT; PLANT CELL; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN STRUCTURE; QUALITY CONTROL; TRANSIENT EXPRESSION; VIRAL CLEARANCE;

ANIMALS; BIOLOGICAL PRODUCTS; DRUG APPROVAL; DRUG INDUSTRY; HUMANS; MOLECULAR FARMING; PLANT PROTEINS; PLANTS, GENETICALLY MODIFIED; RECOMBINANT PROTEINS; TECHNOLOGY, PHARMACEUTICAL;

EID: 84881354730     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612811319310002     Document Type: Article

References (66)

1. Hiatt AH, Caffertey R, Bowdish K. Production of antibodies in transgenic plants. Nature 1989; 342: 76-78.
2. Paul M, van Dolleweerd C, Drake PM, et al. Molecular Pharming: future targets and aspirations. Hum Vaccin. 2011; 7: 375-382.
3. Fischer R, Schillberg S, Hellwig S, Twyman RM, Drossard J. GMP issues for plant-derived recombinant proteins. Biotechnol Adv 2012; 30: 434-9.
4. Ma JKC, Drake PMW, Christou P. The production of recombinant pharmaceutical proteins in plants. Nat Rev Genet 2003; 4: 794-805.
5. Twyman RM, Stoger E, Schillberg S, Christou P, Fischer R. Molecular farming in plants: Host systems and expression technology. Trends Biotechnol 2003; 21: 570-78.
6. Twyman RM, Schillberg S, Fischer R. Transgenic plants in the biopharmaceutical market. Expert Opin Emerg Drugs 2005; 10: 185-218.
7. Buonaguro FM, Butler-Ransohoff J-E. PharmaPlant: the new frontier in vaccines. Expert Rev Vaccin 2010; 9: 805-7.
8. Kusnadi AR, Evangelista RL, Hood EE, Howard JA, Nikolov ZL. Processing of transgenic corn seed and its effect on the recovery of recombinant -glucuronidase. Biotech Bioeng 1998; 60: 44-52.
9. Hood EE. From green plants to industrial enzymes. Enzyme & Microbial Technol 2002; 30: 279-83.
10. Hood EE, Witcher DR, Maddock S, et al. Commercial production of avidin from transgenic maize: characterization of transformant, production, processing, extraction and purification. Mol Breeding 1997; 3: 291-306.
11. Witcher D, Hood EE, Peterson D, et al. Commercial production of glucuronidase (GUS): a model system for the production of proteins in plants. Mol Breeding 4: 301-12.
12. Streatfield SJ, Lane JR, Brooks CA, et al. Corn as a production system for human and animal vaccines. Vaccine 2003; 21: 812-5.
13. Hood EE, Woodard SL, Horn ME. Monoclonal antibody manufacturing in transgenic plantsmyths and realities. Curr Opin Biotechnol 2002; 13: 630-5.
14. Lamphear BJ, Streatfield SJ, Jilka JM, et al. Delivery of subunit vaccines in maize seed. J Control Release 2002 85: 169-80.
15. Menkhaus TJ, Bai Y, Zhang CM, Nikolov ZL, Glatz CE. Considerations for the recovery of recombinant proteins from plants. Biotechnol Prog 2004; 20: 1001-14.
16. Nikolov ZL, Woodard SL. Downstream processing of recombinant proteins from transgenic feedstock. Curr Opin Biotechnol 2004; 15: 479-86.
17. Wilken LR, Nikolov ZL. Recovery and purification of plant-made recombinant proteins. Biotechnol Adv. 2012; 30: 419-33.
18. Azzoni AR, Kusnadi AR, Miranda EA, Nikolov ZL. Recombinant aprotinin produced transgenic corn seed: extraction and purification studies. Biotechnol Bioeng 2002; 80: 268-76.
19. Azzoni AR, Farinas CS, Miranda EA. Transgenic corn seed for recombinant protein production: relevant aspects on the aqueous extraction of native components. J Sci Food Agric 2005; 85: 609-14.
20. Zhong Q, Xu L, Zhang C, Glatz C. Purification of recombinant aprotinin from transgenic corn germ fraction using ion exchange and hydrophobic interaction chromatography. Appl Microbiol Biotechnol 2007; 76: 607-13.
21. Pogue GP, Vojdani F, Palmer KE, et al. Production of pharmaceutical-grade recombinant aprotinin and a monoclonal antibody product using plant-based transient expression systems. Plant Biotechnol 2010; 8: 638-54.
22. Wilken LR, Nikolov ZL. Factors influencing recombinant human lysozyme extraction and cation exchange adsorption. Biotechnol Progr 2006; 22: 745-52.
23. Wilken LR, Nikolov ZL. Evaluation of alternatives for human lysozyme purification from transgenic rice: impact of phytic acid and buffer. Biotechnol Progr 2010; 26: 1303-11.
24. Giritch A, Marillonnet S, Engler C, et al. Rapid high-yield expres-sion of full-size IgG antibodies in plants coinfected with noncom-peting viral vectors. Proc Natl Acad Sci USA 2006; 103: 14701-6.
25. Sainsbury F, Lomonossoff GP. Extremely high-level and rapid protein production in plants without the use of viral replication. Plant Physiol 2008; 148: 1212-8.
26. Vézina LP, Faye L, Lerouge P, et al. Transient coexpression for fast and high-yield production of antibodies with human-like N-glycans in plants. Plant Biotechnol J 2009; 7: 442-55.
27. Huang Z, Phoolcharoen W, Lai H, et al. High-level rapid produc-tion of full-size monoclonal antibodies in plants by a single-vector DNA replicon system. Biotechnol Bioeng 2010; 106: 9-17.
28. Pogue GP, Vojdani F, Palmer KE, et al. Production of pharmaceu-tical-grade recombinant aprotinin and a monoclonal antibody prod-uct using plant-based transient expression systems. Plant Biotech-nol J 2010; 8: 638-654.
29. Cardi T, Lenzi P, Maliga P. Chloroplasts as expression platform for plant-produced vaccines. Expert Rev Vaccin 2010; 9: 893-911.
30. Gomord V, Fitchette AC, Menu-Bouaouiche L, et al. Plant-specific glycosylation patterns in the context of therapeutic protein produc-tion. Plant Biotechnol J 2010; 8: 564-87.
31. Sriraman R, Bardor M, Sack M, et al. Recombinant anti-hCG anti-bodies retained in the endoplasmic reticulum of transformed plants lack core-xylose and core-(1,3)-fucose residues. Plant Biotechnol J 2004; 2: 279-87.
32. Triguero A, Cabrera G, Cremata JA, Yuen CT, Wheeler J, Ramírez NI. Plant-derived mouse IgG monoclonal antibody fused to KDEL endoplasmic reticulum-retention signal is N-glycosylated homoge-neously throughout the plant with mostly high-mannose-type N-glycans. Plant Biotechnol J 2005; 3: 449-57.
33. Strasser R, Castilho A, Stadlmann J, et al. Improved virus neutralization by plant-produced anti-HIV antibodies with a homogeneous 1,4-galactosylated Nglycan profile. J Biol Chem 2009; 284: 20479-85.
34. Castilho A, Strasser R, Stadlmann J, et al. In planta protein sialylation through overexpression of the respective mammalian pathway. J Biol Chem 2010; 285: 15923-30.
35. FDA/USDA. Draft guidance. Drugs, biologics, and medical devices derived from bioengineered plants for use in humans and animals. FDA, Rockville MD, 2002. http://www.fda.gov/downloads/AnimalVeterinary/GuidanceComplianceEnforcement/GuidanceforIndustry/UCM055424.pdf
36. EMEA Committee for Proprietary Medicinal Products (CPMP). Points to consider on quality aspects of medicinal products containing active substances produced by stable transgene expression in higher plants (EMEA/CPMP/BWP/764/02). EMA, London UK, 2002.
37. Spok A, Twyman RM, Fischer R, Ma JKC, Sparrow PAC. Evolution of a regulatory framework for plant-made pharmaceuticals. Trends Biotechnol 2008; 26: 506-17.
38. Aviezer D, Almon-Brill E, Shaaltiel Y, et al. Novel enzyme replacement therapy for Gaucher disease: ongoing Phase III clinical trial with recombinant human glucocerebrosidase expressed in plant cells. Mol Genet Metab 2009; 96: S13-4.
39. Aviezer D, Brill-Almon E, Shaaltiel Y, et al. A plant-derived recombinant human glucocerebrosidase enzyme-a preclinical and phase I investigation. PLoS ONE 2009; 4: e4792.
40. Tiwari S, Verma PC, Singh PK, Tuli R. Plants as bioreactors for the production of vaccine antigens. Biotechnol Adv 2009; 27: 449-67.
41. Xu J, Ge X, Dolan MC. Towards high-yield production of pharma-ceutical proteins with plant cell suspension cultures. Biotechnol Adv 2011; 29: 278-99.
42. EMEA Committee for Proprietary Medicinal Products (CPMP). Guideline on the quality of biological active substances produced by stable transgene expression in higher plants (EMEA/CHMP/BWP/48316/2006). EMA, London UK, 2008.
43. Whaley KJ, Hiatt A, Zeitlin L. Emerging antibody products and Nicotiana manufacturing. Hum Vaccine 2011; 7: 349-356.
44. Tremblay R, Wang D, Jevnikar AM, Ma S. Tobacco, a highly efficient green bioreactor for production of therapeutic proteins. Biotechnol Adv. 2010; 28: 214-21.
45. Shaaltiel Y, Bartfeld D, Hashmueli S, et al. Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher's disease using a plant cell system, Plant Biotechnol J 2007; 5: 579-90.
46. Cox KM, Sterling JD, Regan JT, et al. Glycan optimization of a human monoclonal antibody in the aquatic plant Lemna minor. Nature Biotechnol 2006; 24: 1591-7.
47. McCormick AA, Reddy S, Reinl SJ, et al. Plant-produced idiotype vaccines for the treatment of non-Hodgkin's lymphoma: safety and immunogenicity in a phase 1 clinical study. Proc Natl Acad Sci USA 2008; 105: 101031-6.
48. Bendandi M, Marillonnnet S, Kandzia R, et al. Rapid, high-yield production in plants of individualized idiotype vaccines for non-Hodgkin's lymphoma. Ann Oncol 2010; 21: 2420-7.
49. D'Aoust MA, Couture MM, Charland N, et al. The production of hemagglutinin-based virus-like particles in plants: A rapid, efficient and safe response to pandemic influenza. Plant Biotechnol J 2010; 8: 607-19.
50. D'Aoust MA, Lavoie PO, Couture MM, et al. Influenza virus-like particles produced by transient expression in Nicotiana benthamiana induce a protective immune response against a lethal viral challenge in mice. Plant Biotechnol J 2008; 6: 930-40.
51. Rappuoli R, Dormitzer PR. Influenza: Options to improve pandemic preparation. Science 2012; 336: 1531-3.
52. Pandey A, Singh N, Mittal SK. Egg-independent vaccine strategies for highly pathogenic H5N1 influenza viruses. Human Vaccines 2010; 6: 178-88.
53. Landry N, Ward BJ, Trepanier S, et al. Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza. PLoS ONE 2010; 5: e15559.
54. Shoji Y, Chichester JA, Bi H, et al. Plant-expressed HA as a seasonal influenza vaccine candidate. Vaccine 2008; 26: 2930-4.
55. Shoji Y, Chichester JA, Jones M, et al. Plant-based rapid production of recombinant subunit hemagglutinin vaccines targeting H1N1 and H5N1 influenza. Human Vaccines 2011; 7: 41-50.
56. Ramessar K, Sabalza M, Miralpeix B, Capell T, Christou P. Can microbicides turn the tide against HIV? Curr Pharm Des 2010; 16: 468-85.
57. Ramessar K, Rademacher T, Sack M, et al.Cost-effective production of a vaginal protein microbicide to prevent HIV transmission. Proc Natl Acad Sci USA 2008; 105: 3727-32.
58. Rademacher T, Sack M, Arcalis E, et al. Recombinant antibody 2G12 produced in maize endosperm efficiently neutralizes HIV-1 and contains predominantly single-GlcNAc N-glycans. Plant Biotechnol J 2008; 6: 189-201.
59. Naqvi S, Ramessar K, Farre G, et al. High value products from transgenic maize. Biotechnol Adv 2011; 29: 40-53.
60. Yusibov V, Streatfield SJ, Kushnir N. Clinical development of plant-produced recombinant pharmaceuticals. Vaccines, antibodies and beyond. Human Vaccines 2011; 7: 313-21.
61. Soria-Guerra RE, Rosales-Mendoza S, Moreno-Fierros L, López-Revilla R, Alpuche-Solís AG. Oral immunogenicity of tomatoderived sDPT polypeptide containing Corynebacterium diphtheriae, Bordetella pertussis and Clostridium tetani exotoxin epitopes. Plant Cell Rep. 2011; 30: 417-24.
62. Ogawa M, Kumamaru T, Satoh H, et al. Purification of protein bodyi of rice seed and its polypeptide composition. Plant Cell Physiol 1987; 28: 1517-27.
63. Zimmermann J, Saalbach I, Jahn D, et al. Antibody expressing pea seeds as fodder for prevention of gastrointestinal parasitic infections in chickens. BMC Biotechnol 2009; 9: 79.
64. Verma D, Moghimi B, LoDuca PA, et al. Oral delivery of bioencapsulated coagulation factor IX prevents inhibitor formation and fatal anaphylaxis in hemophilia B mice. Proc Natl Acad Sci USA 2010; 107: 7101-6.
65. Buyel JF, Fischer R. Predictive models for transient protein expression in tobacco (Nicotiana tabacum L.) can optimize process time, yield, and downstream costs. Biotechnol Bioeng 2012; 109: 2575-88.
66. Buyel JF, Kaever T, Buyel JJ, Fischer R. Predictive models for the accumulation of a fluorescent marker protein in tobacco leaves according to the promoter/5'UTR combination. Biotechnol Bioeng 2013; 110: 471-82.